English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Sanofi Us
Press release submission
| May 8, 2018
SANOFI US: Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients
Carol Ostrow
| Oct 7, 2017
Dupixent gains approval as atopic dermatitis treatment in Europe
Nicholas Gueguen
| Jul 23, 2017
Study: Dupixent used with topical corticosteroids improves atopic dermatitis
Nicholas Gueguen
| Jul 1, 2017
FDA OKs Kevzara for moderate to severe rheumatoid arthritis
Ruth de Jauregui
| May 7, 2017
Survey finds majority of rheumatoid arthritis patients living in pain
Robert Hadley
| Apr 15, 2017
Toujeo maker touts drug’s ability to lower blood sugar
Erianne Leatherman
| Apr 5, 2017
Sanofi Genzyme expands Multiple Myeloma Journey Partners program
Ruth de Jauregui
| Apr 2, 2017
FDA approves Dupixent for atopic dermatitis
Trending
+
Community
Patient Daily
| Apr 17, 2025
ENT Practice Expert: OTO Forum 2025 will feature 'at least four topics that stand out as vital for doctors'
+
Pharmaceuticals
Patient Daily
| Apr 17, 2025
UCSF neurosurgeon: 'The idea that 340B is about helping the poor is a fiction'
+
Pharmaceuticals
Patient Daily
| Apr 22, 2025
National Consumers League CEO: 340B program abuse is 'a financial bonanza for non-profit hospitals'
+
Pharmaceuticals
Patient Daily
| Apr 23, 2025
State Sen. Baldacci: 340B reform ‘could help hospitals alone to the tune of 50 to 70 million per year'
